Torii Pharmaceutical Co. Ltd.
https://www.torii.co.jp/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Torii Pharmaceutical Co. Ltd.
Four Major Approval Decisions To Watch Out For In Q2
Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.
Asia Deal Watch: Takeda Keeps Up Hectic Deals Pace Via Three New Alliances
Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.
Latest Japan Approvals Include World-First For Pabinafusp
A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.
Yescarta Becomes Japan’s Second Approved CAR-T
Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing.
Company Information
- Industry
- Pharmaceuticals